MA56021A - Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 - Google Patents

Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Info

Publication number
MA56021A
MA56021A MA056021A MA56021A MA56021A MA 56021 A MA56021 A MA 56021A MA 056021 A MA056021 A MA 056021A MA 56021 A MA56021 A MA 56021A MA 56021 A MA56021 A MA 56021A
Authority
MA
Morocco
Prior art keywords
inhibitors
quinazoline derivatives
amino quinazoline
amino
derivatives
Prior art date
Application number
MA056021A
Other languages
English (en)
Inventor
Charles Baker-Glenn
Matteo Biagetti
Paolo Bruno
Claudio Fiorelli
Kim Louise Hirst
Daniele Pala
Daniela Pizzirani
Paolo Ronchi
De Poël Hervè Van
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA56021A publication Critical patent/MA56021A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MA056021A 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 MA56021A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19177604 2019-05-31
EP19201168 2019-10-02

Publications (1)

Publication Number Publication Date
MA56021A true MA56021A (fr) 2022-04-06

Family

ID=70861506

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056021A MA56021A (fr) 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
MA056022A MA56022A (fr) 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA056022A MA56022A (fr) 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Country Status (20)

Country Link
US (2) US20230092892A1 (fr)
EP (2) EP3976179A1 (fr)
JP (3) JP7641917B2 (fr)
KR (2) KR102921974B1 (fr)
CN (3) CN118239931A (fr)
AU (2) AU2020281923B2 (fr)
BR (2) BR112021022099A2 (fr)
CA (2) CA3139018A1 (fr)
CL (1) CL2021003165A1 (fr)
CO (1) CO2021017031A2 (fr)
GE (2) GEAP202515818A (fr)
IL (1) IL288405A (fr)
MA (2) MA56021A (fr)
MX (2) MX2021014115A (fr)
PE (1) PE20220934A1 (fr)
PH (1) PH12021552881A1 (fr)
SA (1) SA521430920B1 (fr)
SG (1) SG11202112187YA (fr)
WO (2) WO2020239952A1 (fr)
ZA (1) ZA202108273B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102921974B1 (ko) * 2019-05-31 2026-02-05 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 아미노 퀴나졸린 유도체
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
KR102923602B1 (ko) * 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
LT3976597T (lt) 2019-05-31 2024-10-10 Janssen Pharmaceutica Nv Nf-κb indukuojančios kinazės mažos molekulės inhibitoriai
WO2022063205A1 (fr) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 Composé aryl formamide, son procédé de préparation et ses utilisations médicales
KR20230093300A (ko) * 2020-10-20 2023-06-27 쑤저우 젤겐 바이오파마슈티칼즈 컴퍼니 리미티드 치환된 벤조 또는 피리도피리미딘 아민계 억제제 및 이의 제조 방법과 응용
WO2022112491A1 (fr) * 2020-11-27 2022-06-02 Chiesi Farmaceutici S.P.A. Dérivés de (aza)quinoléine 4-amines servant d'inhibiteurs de p2x3
CA3196333A1 (fr) * 2020-11-27 2022-06-02 Claudio FIORELLI Derives d'amino-quinazoline utilises en tant qu'inhibiteurs de p2x3
CN112661803A (zh) * 2020-12-17 2021-04-16 上海药明康德新药开发有限公司 DNA编码化合物库构建中On-DNA 4-胺基喹唑啉化合物的合成方法
IL303965A (en) 2020-12-22 2023-08-01 Mekanistic Therapeutics Llc Transmuted heteroaryl aminobenzyl compounds as EGFR and/or PI3K inhibitors
CN114907284B (zh) * 2021-02-10 2023-11-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN115677601B (zh) * 2021-07-29 2025-06-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2024235225A1 (fr) * 2023-05-15 2024-11-21 苏州泽璟生物制药股份有限公司 Inhibiteur de cycle fusionné à la pyrimidine substitué, son procédé de préparation et son utilisation
AR132741A1 (es) 2023-05-22 2025-07-23 Chiesi Farm Spa Sales de derivados de aminoquinazolina
AU2024274559A1 (en) 2023-05-22 2026-01-22 Chiesi Farmaceutici S.P.A. Process and intermediates for the preparation of a p2x3 inhibitor
WO2025101598A1 (fr) * 2023-11-07 2025-05-15 Zeno Management, Inc. Composés pyrimidiques bicycliques, procédés et utilisations associés

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
DK1725540T5 (da) * 2004-03-05 2012-10-22 Hoffmann La Roche Diaminopyrimidiner som p2x3- og p2x2/3-antagonister
ES2376642T3 (es) * 2005-08-15 2012-03-15 F. Hoffmann-La Roche Ag Derivados de piperidina y de piperazina como antagonistas del p2x3.
CA2620034C (fr) 2005-09-01 2013-10-01 F. Hoffmann-La Roche Ag Diaminopyrimidines comme modulateurs p2x3 et p2x2/3
EP2592070B1 (fr) 2006-06-29 2016-08-31 F. Hoffmann-La Roche AG Arylamides de tétrazole substitués
EP2136639B1 (fr) 2007-04-02 2016-03-09 Evotec AG Composes heterocycliques fusionnes avec pyrid-2-yl, et leurs compositions et utilisations
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
CN104058999A (zh) 2008-02-29 2014-09-24 伊沃泰克股份公司 酰胺化合物、组合物及其应用
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2015006437A (es) 2012-12-27 2015-08-14 Hoffmann La Roche Inhibidores de la enzima catecol-o-metiltransferasa (comt).
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
US20170239249A1 (en) 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
WO2016084922A1 (fr) 2014-11-28 2016-06-02 塩野義製薬株式会社 Dérivé 1,2,4-triazine et composition pharmaceutique correspondante
WO2016088838A1 (fr) 2014-12-04 2016-06-09 塩野義製薬株式会社 Dérivé de purine et composition pharmaceutique le contenant
AU2015359626B2 (en) 2014-12-09 2020-07-23 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
WO2017011729A1 (fr) 2015-07-16 2017-01-19 Patara Pharma, LLC Polythérapies pour le traitement de maladies pulmonaires
HUE061764T2 (hu) 2015-09-29 2023-08-28 Afferent Pharmaceuticals Inc Diaminopirimidin-P2X3 és P2X2/3 receptor modulátorok felhasználásra köhögés kezelésében
US10508106B2 (en) 2015-11-25 2019-12-17 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
AU2017289158C1 (en) * 2016-06-30 2020-07-23 Gilead Sciences, Inc. 4,6-diaminoquinazolines as Cot modulators and methods of use thereof
AU2017312561B2 (en) 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP3558979B1 (fr) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Nouvelles quinazolines substituées benzylamino et dérivés en tant qu'inhibiteurs de sos1
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
EP3619193B1 (fr) * 2017-05-05 2023-03-22 Hepanova, Inc. Composés amino-aryl-benzamide et leurs procédés d'utilisation
KR102923602B1 (ko) 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
KR102921974B1 (ko) 2019-05-31 2026-02-05 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 아미노 퀴나졸린 유도체

Also Published As

Publication number Publication date
KR20220016498A (ko) 2022-02-09
CN114269432B (zh) 2024-05-07
CN118239931A (zh) 2024-06-25
JP2022534303A (ja) 2022-07-28
EP3976180A1 (fr) 2022-04-06
CN113891745A (zh) 2022-01-04
MX2021014113A (es) 2021-12-10
US20220227749A1 (en) 2022-07-21
BR112021022099A2 (pt) 2021-12-28
KR102921974B1 (ko) 2026-02-05
KR102921972B1 (ko) 2026-02-05
IL288405A (en) 2022-01-01
US20230092892A1 (en) 2023-03-23
WO2020239952A1 (fr) 2020-12-03
WO2020239951A1 (fr) 2020-12-03
US12466820B2 (en) 2025-11-11
CO2021017031A2 (es) 2022-01-17
PE20220934A1 (es) 2022-05-31
GEAP202515818A (en) 2025-07-10
SG11202112187YA (en) 2021-12-30
AU2020285336B2 (en) 2026-03-19
CN114269432A (zh) 2022-04-01
AU2020281923A1 (en) 2022-01-06
MA56022A (fr) 2022-04-06
NZ782235A (en) 2025-03-28
JP7644029B2 (ja) 2025-03-11
CL2021003165A1 (es) 2022-09-23
JP2022534751A (ja) 2022-08-03
ZA202108273B (en) 2023-07-26
AU2020285336A1 (en) 2022-01-06
CN113891745B (zh) 2024-05-07
EP3976179A1 (fr) 2022-04-06
AU2020281923B2 (en) 2026-03-19
PH12021552881A1 (en) 2022-07-25
KR20220016499A (ko) 2022-02-09
JP7641917B2 (ja) 2025-03-07
SA521430920B1 (ar) 2025-05-21
CA3139018A1 (fr) 2020-12-03
JP2025098014A (ja) 2025-07-01
MX2021014115A (es) 2021-12-10
BR112021021738A2 (pt) 2021-12-28
GEP20257823B (en) 2025-11-10
CA3139019A1 (fr) 2020-12-03

Similar Documents

Publication Publication Date Title
MA56021A (fr) Dérivés d&#39;amino quinazoline servant d&#39;inhibiteurs de p2x3
EP3976624A4 (fr) Inhibiteur de protéine kinase dépendante de l&#39;adn
MA51616A (fr) Inhibiteurs d&#39;adn-pk
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l&#39;adn
ME03404B (fr) Dérivés d&#39;amides polycycliques comme inhibiteurs de la cdk9
EP3906029A4 (fr) Inhibiteurs de l&#39;interaction ménine-mll
EP3999517A4 (fr) Inhibiteurs de cd73
MA52004A (fr) Inhibiteurs d&#39;o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3919491A4 (fr) Inhibiteur d&#39;akt
EP4039536A4 (fr) Rail de coulissement d&#39;accueil
MA54521A (fr) Dérivés d&#39;oxopyridine substitués
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu&#39;inhibiteurs de ccr6
EP3820980A4 (fr) Compositions d&#39;esterquats
EP4069688C0 (fr) Composés aminés hétéroaromatiques bicycliques fusionnés à action pesticide
EP3774739A4 (fr) Dérivés d&#39;urée cyclique fusionnés utilisés comme antagonistes de crhr2
EP3992176A4 (fr) Antagoniste d&#39;ep2
EP4043450A4 (fr) Dérivés 2h-benzopyrane utilisables en tant qu&#39;inhibiteurs de crac
EP3986411A4 (fr) Inhibiteurs à petites molécules de tyrosine kinase src
MA53648A (fr) Inhibiteurs d&#39;o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3917926C0 (fr) Dérivés d&#39;imidazoquinoline amine, composition pharmaceutique, utilisation de ceux-ci
EP3877475A4 (fr) Compositions synergiques d&#39;inhibiteur de corrosion
MA53164A (fr) Dérivés de tyrosine amide utilisés en tant qu&#39;inhibiteurs de la rho-kinase
MA51283A (fr) Dérivés de tyrosine en tant qu&#39;inhibiteurs de kinase rho
EP3913022A4 (fr) Agent de revêtement d&#39;ancrage
EP3855516A4 (fr) Composition d&#39;étanchéité